Morning Overview on MSN
Study shows chemo drug azacitidine damages RNA in stressed cells
The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute ...
All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...
New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or ...
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with ...
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...
Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...
Azacitidine showed potential in treating patients with VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, offering high response rates and reducing the use of glucocorticoids.
Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results